Recombinetics today announced a multi-year, exclusive collaborative research and development agreement with Children’s Minnesota, the seventh largest pediatric healthcare system in the country, to produce the first-ever large animal model of Phenylketonuria (PKU). PKU is one of the most common inborn errors of metabolism with a cumulative incidence of approximately [...]
Recombinetics announced the development of the first-of-their-kind gene-edited swine models for Neurofibromatosis Type 1 (NF1). Partially funded by the Children’s Tumor Foundation, and in collaboration with the University of Minnesota, these models are for use in preclinical safety and efficacy testing of therapeutics for this debilitating genetic disease affecting 1 [...]
Recombinetics announces the receipt of two Small Business Innovative Research (SBIR) grant awards from the National Institutes of Health totaling more than $700,000. The first grant from the National Institute on Aging is to develop a genetically accurate swine model of Alzheimer’s disease. The second grant from the National Institute [...]
ST. PAUL, MINNESOTA – Recombinetics, a global biotechnology leader in gene editing of livestock for human therapeutics and food production applications, has been awarded a $358,338 Phase I Small Business Innovative Research (SBIR) grant from the National Institute on Aging, National Institutes of Health (NIH) to create a genetically accurate [...]